Gastroesophageal Junction Carcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) [Phase 3]
Phase 3 trial examining pembrolizumab plus chemoradiation versus placebo in esophageal cancer has completed.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays [NA]
A clinical trial is evaluating the PAGODA algorithm for adjusting chemotherapy doses to prevent unplanned treatment delays. The study is cur…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) [Phase 2]
Phase 2 clinical trial update on Givastomig combined with nivolumab and chemotherapy for CLDN18.2-positive metastatic gastric cancer; the st…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer [Phase 2]
Phase II trial evaluating the effect of itraconazole on pathologic complete response rates in resectable esophageal cancer is currently recr…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]
Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
A clinical trial evaluating nivolumab for early-stage esophageal or gastroesophageal junction cancer has been terminated.